Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Exact Sciences Corp (EXAS) USD0.01

Sell:$96.00 Buy:$96.27 Change: $2.20 (2.24%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Sell:$96.00
Buy:$96.27
Change: $2.20 (2.24%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Sell:$96.00
Buy:$96.27
Change: $2.20 (2.24%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.

Contact details

Address:
5505 ENDEAVOR LANE
MADISON
53719
United States
Telephone:
+1 (608) 2845700
Website:
www.exactsciences.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EXAS
ISIN:
US30063P1057
Market cap:
$17.58 billion
Shares in issue:
171.95 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Kevin Conroy
    Chairman of the Board, President, Chief Executive Officer
  • Jeffrey Elliott
    Chief Financial Officer, Chief Operating Officer, Executive Vice President
  • D. Scott Coward
    Senior Vice President, Chief Administrative Officer, General Counsel, Secretary
  • Ana Hooker
    Senior Vice President, Operations
  • Graham Lidgard
    Chief Scientific Officer, Emeritus
  • Jake Orville
    General Manager - Pipeline
  • Gisela Paulsen
    General Manager - Precision Oncology

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.